China-based Broncus Medical Inc., (HKG: 2216), a provider of precision intervention solutions focused on lung diseases, has announced the start of its first regulatory clinical study for its targeted lung denervation (TLD) radiofrequency ablation system. This multi-center, randomized study will be conducted across 26 centers, aiming to assess the safety and efficacy of the TLD system in patients suffering from chronic obstructive pulmonary disease (COPD).
Targeted Lung Denervation: A Promising Approach for COPD Treatment
Targeted lung denervation is an emerging technology designed to treat COPD by achieving denervation through deep tissue radiofrequency ablation in the area where the bronchial Vagus nerve is enriched. This procedure aims to reduce airway obstruction across the entire lung, thereby treating COPD effectively. The technique’s significance was recognized in the 2023 Global Initiative for Chronic Obstructive Lung Disease (GLOD) held in November last year, highlighting its potential impact on the treatment landscape for COPD.
Clinical Study Design and Significance
The clinical study’s design involves a rigorous multi-center approach to evaluate the TLD system’s performance in real-world settings. The study’s outcomes could significantly influence the future of COPD treatment, offering a new therapeutic option for patients and contributing to the advancement of precision intervention solutions in lung disease management.-Fineline Info & Tech
